- Home
- WOK vs ABVC Comparison
WOK vs ABVC Comparison
Compare WOK & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- ABVC
- Stock Information
- Founded
- WOK 2002
- ABVC 2015
- Country
- WOK China
- ABVC United States
- Employees
- WOK N/A
- ABVC N/A
- Industry
- WOK
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- ABVC Health Care
- Exchange
- WOK NYSE
- ABVC Nasdaq
- Market Cap
- WOK 20.2M
- ABVC 22.1M
- IPO Year
- WOK 2024
- ABVC N/A
- Fundamental
- Price
- WOK $0.71
- ABVC $2.44
- Analyst Decision
- WOK
- ABVC
- Analyst Count
- WOK 0
- ABVC 0
- Target Price
- WOK N/A
- ABVC N/A
- AVG Volume (30 Days)
- WOK 123.6K
- ABVC 312.1K
- Earning Date
- WOK 02-03-2025
- ABVC 08-13-2025
- Dividend Yield
- WOK N/A
- ABVC N/A
- EPS Growth
- WOK N/A
- ABVC N/A
- EPS
- WOK N/A
- ABVC N/A
- Revenue
- WOK $11,506,440.00
- ABVC $508,383.00
- Revenue This Year
- WOK N/A
- ABVC $735.18
- Revenue Next Year
- WOK N/A
- ABVC N/A
- P/E Ratio
- WOK N/A
- ABVC N/A
- Revenue Growth
- WOK N/A
- ABVC 1904.43
- 52 Week Low
- WOK $0.36
- ABVC $0.40
- 52 Week High
- WOK $8.45
- ABVC $2.29
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- ABVC 70.75
- Support Level
- WOK N/A
- ABVC $1.84
- Resistance Level
- WOK N/A
- ABVC $2.29
- Average True Range (ATR)
- WOK 0.00
- ABVC 0.16
- MACD
- WOK 0.00
- ABVC 0.03
- Stochastic Oscillator
- WOK 0.00
- ABVC 87.65
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.